Maternal and neonatal mortality associated with hepatitis E in Bangladesh
There is currently a safe and effective vaccine licensed for use in China. The World Health Organization, however, does not endorse routine vaccination, due in part to a lack of data about the burden of disease. Despite numerous clinical case series demonstrating the poor health outcomes associated with hepatitis E during pregnancy, there are no population-based estimates of maternal or neonatal mortality associated with HEV.
Since HEV is the only cause of acute jaundice that selectively kills pregnant women and their newborns, we reviewed population-based, verbal autopsy studies in HEV endemic Bangladesh to identify what proportion of maternal and neonatal deaths were associated with acute onset of jaundice in the mother preceding her death or the birth of the child. Data from national maternal mortality surveys conducted during 2001 and 2010 suggested that 19-23% of maternal deaths in Bangladesh were preceded by acute onset of jaundice.
A smaller collection of verbal autopsy studies on causes of death among newborns showed that 7-13% of neonatal deaths were associated with an illness of acute jaundice in the mother. Based on these preliminary findings, in November 2014, icddr,b began a study to estimate the population-based incidence of maternal and neonatal mortality due to hepatitis E, combining verbal autopsy data with hospital-based surveillance and laboratory diagnosis. We will present our estimates from the first year of data.
Protection of the public in relation to communicable diseases including prevention or control
Public health or related research
Discuss the impact of Hepatitis E infection on maternal health Describe the contribution of HEV infection to neonatal deaths in Bangladesh
Keyword(s): Maternal and Child Health, International Health
Qualified on the content I am responsible for because: Experience in the area of maternal & neonatal mortality at a large research centre in Bangladesh
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.